CMAB completes antibody development for QureBio 10-Jun-2020 By Ben Hargreaves The Chinese CDMO takes bispecific antibody through to IND-stage in nine months.
NEWS IN BRIEF CMAB to provide development service for ‘first in class’ Chinese-developed biologic 04-Dec-2019 By Ben Hargreaves CMAB Biopharma will provide development and manufacturing services for Fapon Biopharma’s potential oncology drug product.
Chinese CDMO contracted to manufacture Pfizer’s oncology candidate 27-Aug-2019 By Vassia Barba CMAB Biopharma to support Kintor in the clinical development of a potential treatment for liver cancer, ahead of regulatory filing.
